Prusinkiewicz Martin A, Sediqi Sadaf, Li Ying Jie, Goldfarb David M, Asamoah-Boaheng Michael, Wall Nechelle, Lavoie Pascal M, Grunau Brian
Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Heliyon. 2023 Jun;9(6):e17259. doi: 10.1016/j.heliyon.2023.e17259. Epub 2023 Jun 13.
Increasing the interval between the first and second SARS-CoV-2 vaccine doses enhances vaccine immunogenicity, however the optimal timing of the third vaccine is unknown. In this study, we investigated how the time interval between the first and second (V1-V2), or second and third (V2-V3) doses affects immunogenicity after three doses of the BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine.
This is an observational cohort consisting of 360 participants enrolled in the (CORSIP) study. Immune responses to BA.1 and other variants were measured from serum using an ACE2 competitive binding assay for surrogate SARS-CoV-2 neutralization. We fit a multiple linear regression model to estimate the independent association between both the V1-V2 and V2-V3 intervals and serum SARS-CoV-2 neutralization, while adjusting for age, sex, and the V3-to-blood collection interval. We examined vaccine dosing intervals as continuous variables and categorized them into quartiles.
The mean age was 40 years, 45% were female sex (at birth), and the median BA.1 surrogate neutralization was 61% (IQR 38-77%). The multivariate analysis indicated that longer V1-V2 (β = 0.1292, 95% CI: 0.04807-0.2104) and V2-V3 (β = 0.2653, 95% CI: 0.2291-0.3015) intervals were associated with increased surrogate neutralization of BA.1. These results were consistent when examining responses against Spike from other SARS-CoV-2 strains. When categorized into V2-V3 quartiles, the first (56-231 days), and second (231-266 days) quartiles demonstrated decreased BA.1 surrogate neutralization compared to the longest V2-V3 quartile (282-329 days). There was no significant difference in surrogate neutralization between the long (266-282 days) and longest (282-329 days) V2-V3 intervals.
Longer intervals between first, second and third doses are independently associated with increased immunogenicity for all tested SARS-CoV-2 strains. Increasing the intervals between the second and third vaccine doses up to 8.9 months provided additive benefits increasing the immunogenicity of BNT162b2 vaccine schedules.
增加新型冠状病毒2（SARS-CoV-2）疫苗第一剂和第二剂之间的间隔可增强疫苗免疫原性，然而第三剂疫苗的最佳接种时间尚不清楚。在本研究中，我们调查了第一剂和第二剂（V1-V2）或第二剂和第三剂（V2-V3）之间的时间间隔如何影响三剂BNT162b2（Comirnaty，辉瑞-生物科技公司）疫苗后的免疫原性。
这是一个观察性队列，由360名参与（CORSIP）研究的参与者组成。使用ACE2竞争性结合试验从血清中测量对BA.1和其他变体的免疫反应，以替代SARS-CoV-2中和。我们拟合了一个多元线性回归模型，以估计V1-V2和V2-V3间隔与血清SARS-CoV-2中和之间的独立关联，同时调整年龄、性别和V3至采血间隔。我们将疫苗接种间隔作为连续变量进行检查，并将其分为四分位数。
平均年龄为40岁，45%为女性（出生时），BA.1替代中和的中位数为61%（IQR 38-77%）。多变量分析表明，较长的V1-V2（β = 0.1292，95%CI：0.04807-0.2104）和V2-V3（β = 0.2653，95%CI：0.2291-0.3015）间隔与BA.1替代中和增加相关。在检查对其他SARS-CoV-2毒株刺突蛋白的反应时，这些结果是一致的。当分为V2-V3四分位数时，与最长的V2-V3四分位数（282-329天）相比，第一个（56-231天）和第二个（231-266天）四分位数的BA.1替代中和降低。长（266-282天）和最长（282-329天）的V2-V3间隔之间的替代中和没有显著差异。
第一剂、第二剂和第三剂之间较长的间隔与所有测试的SARS-CoV-2毒株免疫原性增加独立相关。将第二剂和第三剂疫苗之间的间隔延长至8.9个月可带来额外益处，增加BNT162b2疫苗接种方案的免疫原性。
